Literature DB >> 16865095

Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways.

Gonzalo Romero1, Elisabeth Sánchez, Marta Pujol, Pilar Pérez, Xavier Codony, Jörg Holenz, Helmut Buschmann, Petrus J Pauwels.   

Abstract

1. Two novel selective 5-HT6 receptor ligands E-6801 (6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide) and E-6837 (5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide) were investigated and compared to the putative 5-HT6 receptor antagonists SB-271046 (5-chloro-N-(4-methoxy-3-(piperazin-1-yl)phenyl)-3-methylbenzo[b]thiophene-2-sulfonamide) and Ro 04-06790 (N-(2,6-bis(methylamino)pyrimidin-4-yl)-4-aminobenzenesulfonamide) using a cAMP-mediated pathway. 2. Forskolin stimulation, to increase the magnitude of agonist cAMP responses, and site-directed mutagenesis of the 5-HT6 receptor, in order to yield constitutively active receptor, were applied. 3. 5-HT (E(max), % over basal: 200), E-6801 (120) and E-6837 (23) induced cAMP formation at the rat 5-HT6 receptor. In the copresence of forskolin, cAMP responses were more potent and enhanced to 294 (5-HT, % over forskolin), 250 (E-6801) and 207 (E-6837), respectively. 5-HT-mediated cAMP formation was dose-dependently blocked by SB-271046 (pA(2): 8.76+/-0.22) and Ro 04-6790 (pA(2): 7.89+/-0.10) and not affected by the copresence of forskolin. Both E-6801 and E-6837 yielded partial antagonism of the 5-HT response in the absence of forskolin, whereas antagonism was either completely absent (E-6801) or attenuated (E-6837) in the copresence of forskolin. Intrinsic activity of these 5-HT6 receptor ligands at a constitutively active human S267K 5-HT6 receptor in Cos-7 cells indicated similar efficacy (E(max), % over basal) for 5-HT (97), E-6801 (91) and E-6837 (100), while Ro 04-6790 (-33) and SB-271046 (-39) were equi-efficacious inverse agonists. 4. The use of either forskolin or a constitutively active S267K 5-HT6 receptor enhances the resolution for monitoring the efficacy of 5-HT6 receptor ligands. E-6801 and E-6837 are potent partial agonists at the 5-HT6 receptor. Ro 04-6790 and SB-271046 appear to act as inverse agonists/antagonists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865095      PMCID: PMC1752021          DOI: 10.1038/sj.bjp.0706827

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT(6) receptor.

Authors:  S M Bromidge; K Griffith; T D Heightman; A Jennings; F D King; S F Moss; H Newman; G Riley; C Routledge; H T Serafinowska; D R Thomas
Journal:  Bioorg Med Chem Lett       Date:  2001-11-05       Impact factor: 2.823

3.  Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling.

Authors:  Warren D Hirst; Bjarke Abrahamsen; Frank E Blaney; Andrew R Calver; Lucia Aloj; Gary W Price; Andrew D Medhurst
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

Review 4.  Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.

Authors:  Jörg Holenz; Petrus J Pauwels; José Luis Díaz; Ramon Mercè; Xavier Codony; Helmut Buschmann
Journal:  Drug Discov Today       Date:  2006-04       Impact factor: 7.851

5.  N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands.

Authors:  M G Russell; R J Baker; L Barden; M S Beer; L Bristow; H B Broughton; M Knowles; G McAllister; S Patel; J L Castro
Journal:  J Med Chem       Date:  2001-11-08       Impact factor: 7.446

6.  5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides.

Authors:  M Bös; A J Sleight; T Godel; J R Martin; C Riemer; H Stadler
Journal:  Eur J Med Chem       Date:  2001-02       Impact factor: 6.514

7.  2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.

Authors:  R A Glennon; M Lee; J B Rangisetty; M Dukat; B L Roth; J E Savage; A McBride; L Rauser; S Hufeisen; D K Lee
Journal:  J Med Chem       Date:  2000-03-09       Impact factor: 7.446

8.  Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).

Authors:  S M Bromidge; S E Clarke; T Gager; K Griffith; P Jeffrey; A J Jennings; G F Joiner; F D King; P J Lovell; S F Moss; H Newman; G Riley; D Rogers; C Routledge; H Serafinowska; D R Smith
Journal:  Bioorg Med Chem Lett       Date:  2001-01-08       Impact factor: 2.823

9.  Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.

Authors:  Anil Purohit; Katharine Herrick-Davis; Milt Teitler
Journal:  Synapse       Date:  2003-03       Impact factor: 2.562

Review 10.  Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors.

Authors:  Milt Teitler; Katharine Herrick-Davis; Anil Purohit
Journal:  Curr Top Med Chem       Date:  2002-06       Impact factor: 3.295

View more
  8 in total

Review 1.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

2.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

3.  E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat.

Authors:  Ian Kendall; Helge A Slotten; Xavier Codony; Javier Burgueño; Peter J Pauwels; Jose M Vela; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-04-20       Impact factor: 4.530

4.  HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.

Authors:  François Degorce; Amy Card; Sharon Soh; Eric Trinquet; Glenn P Knapik; Bing Xie
Journal:  Curr Chem Genomics       Date:  2009-05-28

5.  Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht(6) receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task.

Authors:  M V King; C H Spicer; A J Sleight; C A Marsden; K C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2008-10-07       Impact factor: 4.530

6.  5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms.

Authors:  S Woods; N N Clarke; R Layfield; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

7.  Serotonin 5-HT3 receptor-mediated vomiting occurs via the activation of Ca2+/CaMKII-dependent ERK1/2 signaling in the least shrew (Cryptotis parva).

Authors:  Weixia Zhong; Tarun E Hutchinson; Seetha Chebolu; Nissar A Darmani
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

Review 8.  Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review.

Authors:  Chuang Zhao; K P Rakesh; L Ravidar; Wan-Yin Fang; Hua-Li Qin
Journal:  Eur J Med Chem       Date:  2018-11-22       Impact factor: 6.514

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.